These include delivery of anti-Aβ antibody in Alzheimer’s disease (Roche), recombinant IDS protein in Hunter syndrome (separate clinical trials by JCR Pharmaceuticals Co and Denali Therapeutics), and recombinant progranulin in frontotemporal dementia (Denali Therapeutics), all coupled with anti-TfR BBB-carrier function. This evidence concerns the gene TFRC and mucopolysaccharidosis type 2.